Jason Redman, Senior Medical Director at K36 Therapeutics shared a post on LinkedIn:
“Results from our IIT at the NCI: The Quadruple Immunotherapy for Colorectal Cancer (QuICC) Trial combining vaccine + checkpoint/TGF-beta inhibtor + cytokines.
The four-drug combination resulted in one durable CR in an individual with MSS mCRC but was not reproducible in the larger group.”
Title: The quadruple immunotherapy for colorectal cancer (QuICC) trial for mismatch repair-proficient metastatic colorectal cancer
Authors: Dara Bracken-Clarke , Danielle M Pastor , Jennifer L Marté , Renee N Donahue , James W Hodge , Lisa Cordes , Charalampos S Floudas , Nicholas P Tschernia , Fatima Karzai , Isaac Brownell , Evrim B Turkbey , Patrick Soon-Shiong , Jeffrey Schlom , James L Gulley , Hoyoung M Maeng , Julius Strauss , Jason M Redman
Read The Full Article
Other articles about Immunotherapy on OncoDaily.